Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176782 | 0.81 | CES2 (0.48) | CES2CES1CYP2D6SRCLMNA | |
| SCHEMBL114464 | 0.81 | CYP2D6 (0.48) | CES2CES1CYP2D6SRCLMNA | |
| SCHEMBL777870 | 0.81 | ALDH1A1 (0.55) | CES2CES1CYP2D6SRCLMNA | |
| SCHEMBL9860357 | 0.79 | HCAR2 (0.56) | CES2CES1CYP2D6SRCLMNA | |
| Potassium Ion SCHEMBL27618230 | 0.79 | CES2 (0.47) | CES2CES1CYP2D6SRCLMNA | |
| SCHEMBL4216010 | 0.79 | TSHR (0.57) | CES2CES1LMNAMAPK1KMT2A | |
| SCHEMBL9860354 | 0.79 | HCAR2 (0.56) | CES2CES1CYP2D6SRCLMNA | |
| SCHEMBL28068764 | 0.78 | KMT2A (0.46) | CES2CES1CYP2D6SRCKMT2A | |
| SCHEMBL871450 | 0.77 | ESR1 (0.55) | CES2CES1CYP2D6SRCLMNA | |
| SCHEMBL2362357 | 0.76 | CES2 (0.44) | CES2CES1CYP2D6SRCLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006142-A1 | Ocular tension depressor | FUJISAWA PHARAMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1051415-B1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1280523-A2 | USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF HIGH OCULAR TENSION AND GLAUCOMA | Sucampo AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| EP-0620216-B1 | Benzamide derivatives and their use as vasopressin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-01-08 | — | — | EP | disclosed |
| US-6495542-B1 | SUCH AS 2-METHOXY-N-(2-METHYL-1H-BENZIMIDAZOL-4-YL)-4-(2,3,4,5-TETRAHYDRO-5-OXO-1H-1-BENZAZEPIN-1-YL)CARBONYL-BENZAM IDE; HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-6489324-B2 | TREATING STROKE, ARHTRITIS, CANCER, TISSUE ULCERATION, DECUBITIS ULCER, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCLERITIS, PSORIASIS, AIDS, SEPSIS, AND SEPTIC SHOCK. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020128270-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-1171422-A1 | MMP INHIBITOR | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-16 | — | — | EP | disclosed |
| US-6333324-B1 | FOR THERAPY AND PROPHYLAXIS OF MATRIX METALLOPROTEINASES (MMP) OR TUMOR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.), MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-0356234-B1 | New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-05-11 | — | — | EP | disclosed |
| EP-0583485-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES. | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-02-23 | — | — | EP | disclosed |
| EP-0579833-A1 | ETHANOLAMINE DERIVATIVES WITH ANTI-POLLAKIURIA ACTIVITY. | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-01-26 | — | — | EP | disclosed |
| WO-1993015041-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-05 | — | — | WO | disclosed |
| WO-1992018461-A1 | ETHANOLAMINE DERIVATIVES WITH ANTI-POLLAKIURIA ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-29 | — | — | WO | disclosed |
| US-5047411-A | Antiulcer Agents, H2-Receptor Antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| US-5017703-A | Antiallergens, antiinflammatory | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| US-4935432-A | ANTIALLERGENS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-06-19 | — | — | US | disclosed |
| EP-0356234-A2 | New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
| EP-0324431-A1 | New indolylpiperidine compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128270-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP1, MMP2, TNF | CES2 2063/4885CES1 565/4885CYP2D6 1216/4885 |
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP2, MMP1, TNF | CES2 1863/4885CES1 865/4885CYP2D6 927/4885 |
| US-20040006142-A1 | Ocular tension depressor | TPH2, TPH1, ALDH1A2 | CES2 2740/4885CES1 2523/4885CYP2D6 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.